Major lung cancer drug monitored in nearly 1,000 patients
NCT ID NCT03918304
Summary
This study monitored 923 Korean patients with a specific type of lung cancer who were already prescribed the drug Tagrisso (osimertinib) by their doctors. The goal was to see how safe and effective the drug is in everyday, real-world use, not in a controlled trial. Researchers tracked side effects and whether the cancer responded or stayed under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Busan, South Korea
-
Research Site
Chungcheongbuk-do, South Korea
-
Research Site
Daegu, South Korea
-
Research Site
Daejeon, South Korea
-
Research Site
Gangwon State, South Korea
-
Research Site
Gyeonggi-do, South Korea
-
Research Site
Incheon, South Korea
-
Research Site
Jeollabuk-do, South Korea
-
Research Site
Jeollanam-do, South Korea
-
Research Site
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.